Abstract 1826P
Background
The global incidence of breast cancer is increasing, highlighting the need for attention not only to treatment but also to long-term survivorship issues. Osteoporosis, an age-related bone disorder, presents a significant concern for patients with breast cancer due to its potential impact on morbidity and mortality. This Korean nationwide cohort study aimed to investigate the occurrence and risk factors of osteoporosis among patients with breast cancer, with a specific focus on gender disparities.
Methods
Using data from the Korean National Health Insurance claim database, we identified individuals diagnosed with ductal carcinoma in situ or breast cancer as their primary diagnosis between 2009 and 2015. Patients diagnosed with osteoporosis were determined based on ICD-10 codes (International Classification of Disease) and medication prescriptions. Propensity score matching was performed to minimize confounding variables.
Results
Among 299 male and 80362 female breast cancer patients, a higher prevalence of osteoporosis was observed in females (n=13423(16.7%) vs n=15(5.0%)). Endocrine therapy was associated with an increased risk of osteoporosis, particularly among females (HR 6.37, 95%CI, 3.74-10.89, p<0.001). Age, steroid medication use, and comorbidity burden were also identified as significant risk factors for osteoporosis. Adjusting other variables, females diagnosed with osteoporosis had a higher incidence of only hip or vertebral fractures compared to males (HR 3.96, 95%CI, 1.24-12.64, p=0.020). While overall fracture incidence was higher in males before matching, gender differences were not significant after propensity score matching.
Conclusions
In conclusion, our study highlights the importance of proactive screening and management of osteoporosis in breast cancer patients, with a focus on gender-specific risk factors. These findings emphasize the necessity of comprehensive bone health assessment and preventive measures to improve long-term outcomes and quality of life for breast cancer survivors. Further research is warranted to elucidate the underlying mechanisms of gender differences in osteoporosis risk and evaluate the effectiveness of targeted interventions in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1906P - ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy
Presenter: Evert van Aken
Session: Poster session 12
1907P - Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium
Presenter: Nicolas Bertrand
Session: Poster session 12
1908P - Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Presenter: Panagiotis Filis
Session: Poster session 12
1909TiP - Home-based physical exercise during neoadjuvant treatment for early breast cancer patients (HoPEx-Breast): A pragmatic randomised controlled trial
Presenter: Rita Pichel
Session: Poster session 12
1943P - Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
Presenter: Julie Deutsch
Session: Poster session 12
1944P - Super-enhancer driven NR3C1 expression promotes 5-FU resistance in gastric cancer
Presenter: Bingya Liu
Session: Poster session 12
Resources:
Abstract
1945P - Stroma-derived bIgH3 (βigH3/TGFBI) is the local mediator of pathological TGFβ activity in pancreatic cancer and a target to treat in patients with high fibrotic activity
Presenter: Morten Karsdal
Session: Poster session 12
1946P - SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via inhibiting cystine transportation in gastric cancer
Presenter: Jianfang Li
Session: Poster session 12
Resources:
Abstract
1947P - Organoid establishment from multiple biological sources in biliopancreatic cancers
Presenter: Michele Zanoni
Session: Poster session 12
1948P - Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial
Presenter: Ana Julia de Freitas
Session: Poster session 12